@prefix activity: .
@prefix address: .
@prefix agency: .
@prefix assay: .
@prefix assayCategory: .
@prefix assayTargetLink: .
@prefix biopax3: .
@prefix calbc: .
@prefix calbc-group: .
@prefix carrierLink: .
@prefix certainAgreement: .
@prefix chebi: .
@prefix chembl: .
@prefix chemicalCompound: .
@prefix chemicalCompoundRecord: .
@prefix clan: .
@prefix clinicalResult: .
@prefix clinicalStudy: .
@prefix clinicaltrials: .
@prefix company: .
@prefix confidenceScore: .
@prefix contact: .
@prefix country: .
@prefix cpath: .
@prefix curationLookup: .
@prefix dailymed: .
@prefix dailymed-drugs: .
@prefix dailymed-ingredient: .
@prefix dailymed-instance: .
@prefix databaseReference: .
@prefix dc: .
@prefix dc-term: .
@prefix diseaseontology: .
@prefix diseasome: .
@prefix diseasome-diseases: .
@prefix diseasome-gene: .
@prefix diseasome-instance: .
@prefix documentType: .
@prefix dosageForm: .
@prefix drug: .
@prefix drugbank: .
@prefix drugbank-proteinSequence: .
@prefix drugCategory: .
@prefix drugInteraction: .
@prefix drugTarget: .
@prefix eligibility: .
@prefix entrez-gene: .
@prefix entrez-goterm: .
@prefix entrezgene: .
@prefix enzymeLink: .
@prefix externalIdentifier: .
@prefix externalLink: .
@prefix factforge: .
@prefix family: .
@prefix foaf: .
@prefix formulation: .
@prefix freebase: .
@prefix gene-rif: .
@prefix geneontology: .
@prefix geneSequence: .
@prefix hapmap: .
@prefix indication: .
@prefix intervention: .
@prefix investigator: .
@prefix label: .
@prefix lhgdn: .
@prefix lifeskim: .
@prefix linkedct: .
@prefix linkedct-condition: .
@prefix linkedct-intervention: .
@prefix literatureCitation: .
@prefix lld: .
@prefix location: .
@prefix measurement: .
@prefix meddraSideEffect: .
@prefix mixture: .
@prefix molecularSpecies: .
@prefix molecule: .
@prefix moleculeType: .
@prefix ontotext: .
@prefix organismSpecies: .
@prefix outcomeAnalysis: .
@prefix outcomeMeasure: .
@prefix overallOfficial: .
@prefix owl: .
@prefix owlim: .
@prefix packager: .
@prefix participantFlow: .
@prefix patent: .
@prefix pfam: .
@prefix phenotype: .
@prefix pointOfContact: .
@prefix price: .
@prefix primaryOutcome: .
@prefix product: .
@prefix property: .
@prefix proteinSequence: .
@prefix pubmed: .
@prefix pubmed-article: .
@prefix pubmed-author: .
@prefix pubmed-mesh: .
@prefix pubmed-meshheading: .
@prefix pubmed-qualifier: .
@prefix rdf: .
@prefix rdfs: .
@prefix relationshipType: .
@prefix relontology: .
@prefix reportingGroup: .
@prefix researchStem: .
@prefix responsibleParty: .
@prefix result: .
@prefix resultsBaseline: .
@prefix resultsMeasure: .
@prefix resultsOutcome: .
@prefix secondaryOutcome: .
@prefix sideEffect: .
@prefix sideEffectFrequency: .
@prefix sider: .
@prefix sider-drug: .
@prefix skos: .
@prefix skos-xl: .
@prefix snp: .
@prefix structureType: .
@prefix studyMilestone: .
@prefix studyParticipants: .
@prefix studyPeriod: .
@prefix substructure: .
@prefix symptom: .
@prefix synonym: .
@prefix targetLink: .
@prefix targetType: .
@prefix taxonomy: .
@prefix taxonomyClass: .
@prefix taxonomyKingdom: .
@prefix transporterLink: .
@prefix umls: .
@prefix umls-concept: .
@prefix umls-label: .
@prefix umls-semnetwork: .
@prefix uniprot: .
@prefix uniprot-protein: .
@prefix uniprot-unstable: .
@prefix xsd: .
pubmed-article:1979339 a pubmed:Citation ;
lifeskim:mentions umls-concept:C0021051 , umls-concept:C0086418 , umls-concept:C0597357 , umls-concept:C0017968 , umls-concept:C0019691 , umls-concept:C0031621 , umls-concept:C0108779 , umls-concept:C1414406 , umls-concept:C1704259 , umls-concept:C1160185 , umls-concept:C1705987 ;
pubmed:issue "6" ;
pubmed:dateCreated "1991-1-22" ;
pubmed:abstractText "The interference of the recombinant HIV-1 glycoproteins gp160 and gp120 with the CD3/T cell antigen receptor (TcR)-mediated activation process has been investigated in the CD4+ diphtheria toxoid-specific human P28D T cell clone. Both glycoproteins clearly inhibit the T cell proliferation induced in an antigen-presenting cell (APC)-free system by various cross-linked monoclonal antibodies specific for the CD3 molecule or the TcR alpha chain (up to 80% inhibition). Biochemical studies further demonstrate that exposure of the T cell clone to both glycoproteins (gps) specifically inhibits the CD3/TcR phospholipase C (PLC) transduction pathway, without affecting the CD3/TcR cell surface expression. Thus, inositol phosphate production, phosphatidic acid turnover, intracellular free calcium, and intracellular pH increase induced by CD3/TcR-specific MAbs are specifically impaired in gps-treated P28D T cells. Addition of purified soluble CD4 prevents binding of gps to T cells and overcomes all observed inhibitions. Maximal inhibitions are obtained for long-term exposure of the T cell clone to gps (16 h). No early effect of gps is observed. By contrast, gp160 and gp120 fail to suppress the CD2-triggered functional and biochemical P28D T cell responses. These results demonstrate that, in addition to their postulated role in the alteration of the interaction between CD4 on T lymphocytes and MHC class II molecules on APC, soluble HIV-1 envelope glycoproteins may directly and specifically impair the CD3/TcR-mediated activation of PLC in uninfected T cells via the CD4 molecule." ;
pubmed:commentsCorrections , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ;
pubmed:language "eng" ;
pubmed:journal ;
pubmed:citationSubset "AIM" ;
pubmed:chemical , , , , , , , , , ;
pubmed:status "MEDLINE" ;
pubmed:month "Dec" ;
pubmed:issn "0021-9738" ;
pubmed:author pubmed-author:DebrePP , pubmed-author:KaczorekMM , pubmed-author:AutranBB , pubmed-author:BismuthGG , pubmed-author:CefaiDD , pubmed-author:IdziorekTT ;
pubmed:issnType "Print" ;
pubmed:volume "86" ;
pubmed:owner "NLM" ;
pubmed:authorsComplete "Y" ;
pubmed:pagination "2117-24" ;
pubmed:dateRevised "2009-11-18" ;
pubmed:meshHeading pubmed-meshheading:1979339-Humans , , pubmed-meshheading:1979339-Calcium , pubmed-meshheading:1979339-Phosphatidylinositols , , , , , , , , , pubmed-meshheading:1979339-HIV-1 , , , , ;
pubmed:year "1990" ;
pubmed:articleTitle "Human immunodeficiency virus-1 glycoproteins gp120 and gp160 specifically inhibit the CD3/T cell-antigen receptor phosphoinositide transduction pathway." ;
pubmed:affiliation "Laboratoire d'Immunologie Cellulaire et Tissulaire, Group Hospitalier (GH) Pitié-Salpétrière, Paris, France." ;
pubmed:publicationType "Journal Article" , "In Vitro" , "Research Support, Non-U.S. Gov't" .